Abstract
The evidence that cancer development is a complex and multistep process, characterized by alterations of genes involved in the regulation of proliferation, apoptosis and angiogenesis, has led to development of new therapeutic strategies based on the use of agents able to selectively inhibit key molecules of these pathways. In particular, antisense oligonucleotides (ASOs) have proved their efficacy as targeted therapy in preclinical studies, have been well tolerated and able to modulate target protein expression in clinical studies. Although these agents have shown considerable promise for antitumoral therapy, treatment with ASOs used as single agent does not seem particularly promising because of the multigenic alterations of tumors. Based on these considerations, approaches based on the combination of ASOs targeting oncogenes involved in different molecular pathways have been investigated. Moreover, the role of this novel strategy when integrated with conventional drugs or signaling inhibitors, has been assessed. This review addresses some advances in the ASOs combination and reports the potential application of this strategy for the treatment of human cancer.
Keywords: Antisense, targeted therapy, antineoplastic drugs, proliferation, apoptosis, angiogenesis
Current Pharmaceutical Design
Title: Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy
Volume: 13 Issue: 5
Author(s): C. Leonetti and G. Zupi
Affiliation:
Keywords: Antisense, targeted therapy, antineoplastic drugs, proliferation, apoptosis, angiogenesis
Abstract: The evidence that cancer development is a complex and multistep process, characterized by alterations of genes involved in the regulation of proliferation, apoptosis and angiogenesis, has led to development of new therapeutic strategies based on the use of agents able to selectively inhibit key molecules of these pathways. In particular, antisense oligonucleotides (ASOs) have proved their efficacy as targeted therapy in preclinical studies, have been well tolerated and able to modulate target protein expression in clinical studies. Although these agents have shown considerable promise for antitumoral therapy, treatment with ASOs used as single agent does not seem particularly promising because of the multigenic alterations of tumors. Based on these considerations, approaches based on the combination of ASOs targeting oncogenes involved in different molecular pathways have been investigated. Moreover, the role of this novel strategy when integrated with conventional drugs or signaling inhibitors, has been assessed. This review addresses some advances in the ASOs combination and reports the potential application of this strategy for the treatment of human cancer.
Export Options
About this article
Cite this article as:
Leonetti C. and Zupi G., Targeting Different Signaling Pathways with Antisense Oligonucleotides Combination for Cancer Therapy, Current Pharmaceutical Design 2007; 13 (5) . https://dx.doi.org/10.2174/138161207780162917
DOI https://dx.doi.org/10.2174/138161207780162917 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Nucleus: An Overview of Auger-Electron Radionuclide Therapy
Current Drug Discovery Technologies Melatonin and Melatoninergic Drugs as Therapeutic Agents: Ramelteon and Agomelatine, the Two Most Promising Melatonin Receptor Agonists
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Class II Phosphoinositide 3-Kinases as Potential Novel Drug Targets
Current Signal Transduction Therapy Nanotech Revolution for the Anti-Cancer Drug Delivery through Blood- Brain-Barrier
Current Cancer Drug Targets Patent Selections
Recent Patents on Biomarkers Metabolomics
Current Drug Metabolism Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment
Current Pharmaceutical Design Recent Advances in Curcumin Nanocarriers for the Treatment of Different Types of Cancer with Special Emphasis on In Vitro Cytotoxicity and Cellular Uptake Studies
Nanoscience & Nanotechnology-Asia Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design Measurement and Modeling of Respiration Rate of Tomato (Cultivar Roma) for Modified Atmosphere Storage
Recent Patents on Food, Nutrition & Agriculture Genetic Analysis of CYP2D6 Polymorphism in Indian Populations and its Pharmacogenetic Implications
Current Pharmacogenomics and Personalized Medicine Meet Our Editorial Board Member
Current Medicinal Chemistry Role of Free Fatty Acid Receptor 2 (FFAR2) in the Regulation of Metabolic Homeostasis
Current Drug Targets Vitamin D and Cancer Mortality: Systematic Review of Prospective Epidemiological Studies
Anti-Cancer Agents in Medicinal Chemistry High-level Soluble Expression, Purification, and Functional Characterization of the Recombinant Human Leukemia Inhibitory Factor: A Potential General Strategy for the Recombinant Expression of Cytokines Consisting of Four α-Helices in a Bundle
Protein & Peptide Letters Successful Structure-Based Design of Recent p38 MAP Kinase Inhibitors
Current Topics in Medicinal Chemistry Anticancer Drug Sensitivity Testing, a Historical Review and Future Perspectives
Current Drug Therapy Use of Metformin and Survival of Diabetic Women with Breast Cancer
Current Drug Safety The Pathogenesis of Lung Cancer and Chromosome 11
Current Genomics A Simple Protein Extraction Method for Proteomic Analysis of Diverse Biological Specimens
Current Proteomics